192 results on '"Rendina, Alan R."'
Search Results
2. A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease
3. The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure
4. The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors
5. Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group
6. Exploration of the P1 Residue in CL Protease Inhibitors Leading to the Discovery of a Novel 2-Tetrahydrofuran P1 Replacement
7. In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa
8. Differential activation of recombinant human acetyl-CoA carboxylases 1 and 2 by citrate
9. Active mutants of Escherichia coli dethiobiotin synthetase: effects of mutations on enzyme catalytic and structural properties
10. Dethiobiotin synthetase: the carbonylation of 7,8-diaminononanoic acid proceeds regiospecifically via the N7-carbamate
11. Mechanism of an ATP-dependent carboxylase, dethiobiotin synthetase, based on crystallographic studies of complexes with substrates and a reaction intermediate
12. Mechanistic MALDI-TOF Cell-Based Assay for the Discovery of Potent and Specific Fatty Acid Synthase Inhibitors
13. Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer
14. Biochemical Approaches to Herbicide Discovery
15. Neutral macrocyclic factor VIIa inhibitors
16. Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1
17. Novel phenylalanine derived diamides as Factor XIa inhibitors
18. Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties
19. Pyridine and pyridinone-based factor XIa inhibitors
20. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties
21. Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases
22. Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors
23. Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF–FVIIa inhibitors
24. Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors
25. Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors
26. Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa–Tissue Factor Complex
27. DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors
28. Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors
29. New Allosteric Inhibitors of Mutant IDH1 in Acute Myeloid Leukemia
30. Abstract C38: Novel allosteric IDH1 mutant Inhibitors for differentiation therapy of acute myeloid leukemia
31. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
32. Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors
33. Discovery of Novel P1 Groups for Coagulation Factor VIIa Inhibition Using Fragment-Based Screening
34. The Mechanism of Aldehyde-Induced ATPase Activities of Kinases
35. Phenylimidazoles as Potent and Selective Inhibitors of Coagulation Factor XIa with in Vivo Antithrombotic Activity
36. A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site
37. Highly efficacious factor Xa inhibitors containing α-substituted phenylcycloalkyl P4 moieties
38. Tetrahydroquinoline Derivatives as Potent and Selective Factor XIa Inhibitors
39. Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors
40. Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
41. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa
42. Structure–activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties
43. Sulfonamidolactam inhibitors of coagulation factor Xa
44. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma
45. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa
46. Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications
47. Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa
48. Discovery of Novel P1 Groupsfor Coagulation FactorVIIa Inhibition Using Fragment-Based Screening.
49. In Vitro Evaluation of Apixaban, a Novel, Potent, Selective and Orally Bioavailable Factor Xa Inhibitor.
50. Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.